Phase 3
N/A
Sponsors / Collaborators
Aquestive Therapeutics
New Formulations and Indications
Convection Enhanced Delivery of Anticonvulsant Toxins for the Treatment of Intractable Partial Epilepsy
Preclinical
N/A
Sponsors / Collaborators
University of California Davis; Medgenesis Therapeutix, Epilepsy Foundation (EF)
Sponsors / Collaborators
King Pharmaceuticals; Pfizer
Preclinical
N/A
Sponsors / Collaborators
New York University, School of Medicine, EF
New Formulations and Indications
Topiramate IV: Enhanced Method of Administration in Babies, Older Children and Adults
Preclinical
N/A
Sponsors / Collaborators
University of Minnesota; Ligang Pharmaceuticals (formerly CyDex), EF
Sponsors / Collaborators
Greenwich Biosciences
Disclaimer
The Epilepsy Foundation makes no claims of accuracy of the following data. Although every effort is made to continuously update this list, some errors are inevitable. Companies or academicians or others who are directly involved with any of the therapies listed here are strongly encouraged to keep us updated by contacting [email protected] of any needed changes.